Bellevue Group’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $77.6M | Sell |
234,543
-211,360
| -47% | -$71.9M | 1.85% | 19 |
|
|
2025
Q4 | $177M | Sell |
445,903
-621
| -0.1% | -$275K | 3.36% | 9 |
|
|
2025
Q3 | $204M | Sell |
446,524
-229,843
| -34% | -$93.6M | 4.23% | 5 |
|
|
2025
Q2 | $221M | Sell |
676,367
-91,780
| -12% | -$25.4M | 4.86% | 4 |
|
|
2025
Q1 | $207M | Sell |
768,147
-2,121
| -0.3% | -$545K | 4.65% | 5 |
|
|
2024
Q4 | $181M | Sell |
770,268
-38,827
| -5% | -$10.2M | 3.49% | 11 |
|
|
2024
Q3 | $223M | Sell |
809,095
-110,739
| -12% | -$28.8M | 3.61% | 5 |
|
|
2024
Q2 | $224M | Buy |
919,834
+1,550
| +0.2% | +$245K | 3.63% | 6 |
|
|
2024
Q1 | $137M | Buy |
918,284
+32,966
| +4% | +$5.5M | 2.09% | 14 |
|
|
2023
Q4 | $169M | Sell |
885,318
-9,027
| -1% | -$1.54M | 2.59% | 9 |
|
|
2023
Q3 | $158M | Sell |
894,345
-5,305
| -0.6% | -$1.01M | 2.55% | 7 |
|
|
2023
Q2 | $171M | Buy |
899,650
+16,400
| +2% | +$3.25M | 2.44% | 9 |
|
|
2023
Q1 | $177M | Sell |
883,250
-37,963
| -4% | -$7.98M | 2.57% | 9 |
|
|
2022
Q4 | $219M | Sell |
921,213
-35,549
| -4% | -$7.58M | 2.91% | 8 |
|
|
2022
Q3 | $192M | Sell |
956,762
-101,424
| -10% | -$19.3M | 2.75% | 5 |
|
|
2022
Q2 | $154M | Sell |
1,058,186
-171,377
| -14% | -$24.3M | 2.18% | 11 |
|
|
2022
Q1 | $201M | Sell |
1,229,563
-105,577
| -8% | -$16.1M | 2.33% | 9 |
|
|
2021
Q4 | $226M | Sell |
1,335,140
-73,278
| -5% | -$13.6M | 2.33% | 7 |
|
|
2021
Q3 | $266M | Sell |
1,408,418
-140,674
| -9% | -$26.4M | 2.7% | 6 |
|
|
2021
Q2 | $263M | Sell |
1,549,092
-78,022
| -5% | -$11.4M | 2.56% | 6 |
|
|
2021
Q1 | $230M | Buy |
1,627,114
+23,614
| +1% | +$3.55M | 2.43% | 8 |
|
|
2020
Q4 | $208M | Buy |
1,603,500
+43,695
| +3% | +$5.83M | 2.39% | 8 |
|
|
2020
Q3 | $227M | Sell |
1,559,805
-50,260
| -3% | -$7.14M | 3.14% | 7 |
|
|
2020
Q2 | $238M | Sell |
1,610,065
-165,199
| -9% | -$22.3M | 3.37% | 6 |
|
|
2020
Q1 | $193M | Sell |
1,775,264
-89,519
| -5% | -$10.3M | 3.75% | 5 |
|
|
2019
Q4 | $215M | Sell |
1,864,783
-100,289
| -5% | -$10M | 3.41% | 6 |
|
|
2019
Q3 | $158M | Buy |
1,965,072
+37,678
| +2% | +$2.98M | 2.94% | 7 |
|
|
2019
Q2 | $140M | Buy |
1,927,394
+1,660,089
| +621% | +$127M | 2.39% | 12 |
|
|
2019
Q1 | $25M | Buy |
267,305
+42,920
| +19% | +$3.59M | 1.37% | 20 |
|
|
2018
Q4 | $16.4M | Buy |
224,385
+4,494
| +2% | +$346K | 1.08% | 28 |
|
|
2018
Q3 | $19.2M | Buy |
219,891
+116,391
| +112% | +$11.7M | 1.22% | 25 |
|
|
2018
Q2 | $10.2M | Buy |
103,500
+81,750
| +376% | +$8.11M | 0.87% | 43 |
|
|
2018
Q1 | $2.59M | Sell |
21,750
-350
| -2% | -$45.1K | 0.26% | 68 |
|
|
2017
Q4 | $2.81M | Sell |
22,100
-53,493
| -71% | -$6.72M | 0.29% | 70 |
|
|
2017
Q3 | $8.88M | Sell |
75,593
-49,436
| -40% | -$4.22M | 0.93% | 40 |
|
|
2017
Q2 | $9.97M | Sell |
125,029
-16,871
| -12% | -$1.08M | 1.18% | 34 |
|
|
2017
Q1 | $7.27M | Buy |
141,900
+117,900
| +491% | +$5.45M | 0.97% | 39 |
|
|
2016
Q4 | $899K | Hold |
24,000
| – | – | 0.18% | 89 |
|
|
2016
Q3 | $1.63M | Hold |
24,000
| – | – | 0.29% | 82 |
|
|
2016
Q2 | $1.33M | Hold |
24,000
| – | – | 0.25% | 89 |
|
|
2016
Q1 | $1.51M | Buy |
+24,000
| New | +$1.6M | 0.27% | 86 |
|
Other funds holding ALNY
VPM
VCM
Bellevue Group's ALNY Position: Q1 2026 in Review
Bellevue Group reduced its Alnylam Pharmaceuticals (ALNY) stake by 47% in Q1 2026, selling an estimated $71.9M and leaving 234,543 shares worth $77.6M. The position accounts for 1.85% of the portfolio, ranked #19.
Bellevue Group first reported a position in ALNY in Q1 2016 and has held it in 41 quarters since. The position peaked at $266M in Q3 2021. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.
- Bellevue Group held 234,543 shares of Alnylam Pharmaceuticals worth $77.6M as of Q1 2026.
- Bellevue Group sold 211,360 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $71.9M.
- Alnylam Pharmaceuticals made up 1.85% of Bellevue Group's portfolio in Q1 2026, its #19 holding.
- Bellevue Group first reported a position in Alnylam Pharmaceuticals in Q1 2016 and has held it in 41 quarters since.
- Bellevue Group's Alnylam Pharmaceuticals position peaked at $266M in Q3 2021.
- 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.
Based on Bellevue Group's 13F filing for Q1 2026, filed 15 May 2026.